The ACST chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ACST chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The ACST stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View ACST Detailed Price Forecast - CNN Money||View ACST Detailed Summary - Google Finance|
|View ACST Detailed Summary - Yahoo! Finance||View ACST Stock Research & Analysis - Zacks.com|
|View ACST Trends & Analysis - Trade-Ideas||View ACST Major Holders - Barrons|
|View ACST Call Transcripts - NASDAQ||View ACST Breaking News & Analysis - Seeking Alpha|
|View ACST Annual Report - CompanySpotlight.com||View ACST OTC Short Report - OTCShortReport.com|
|View ACST Fundamentals - TradeKing||View ACST SEC Filings - Bar Chart|
|View Historical Prices for ACST - The WSJ||View Performance/Total Return for ACST - Morningstar|
|View the Analyst Estimates for ACST - MarketWatch||View the Earnings History for ACST - CNBC|
|View the ACST Earnings - StockMarketWatch||View ACST Buy or Sell Recommendations - MacroAxis|
|View the ACST Bullish Patterns - American Bulls||View ACST Short Pain Metrics - ShortPainBot.com|
|View ACST Stock Mentions - StockTwits||View ACST Stock Mentions - PennyStockTweets|
|View ACST Stock Mentions - Twitter||View ACST Investment Forum News - Investor Hub|
|View ACST Stock Mentions - Yahoo! Message Board||View ACST Stock Mentions - Seeking Alpha|
|View Insider Transactions for ACST - SECform4.com||View Insider Transactions for ACST - Insider Cow|
|View ACST Major Holdings Summary - CNBC||View Insider Disclosure for ACST - OTC Markets|
|View Insider Transactions for ACST - Yahoo! Finance||View Institutional Holdings for ACST - NASDAQ|
|View ACST Stock Insight & Charts - FinViz.com||View ACST Investment Charts - StockCharts.com|
|View ACST Stock Overview & Charts - BarChart||View ACST User Generated Charts - Trading View|
Acasti Pharma Announces Closing of $19.1 Million Underwritten Public Offering of Common Shares
Posted on Thursday October 11, 2018
MONTRÉAL, Oct. 11, 2018 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, announced today the closing of its previously announced underwritten public offering of 16,600,000 common shares in the United States at a price to the public of $1.00 per share. In addition, the underwriters fully exercised their option to purchase 2,490,000 additional common shares at the same public offering price. All common shares in the offering were offered by Acasti Pharma. Aegis Capital Corporation acted as a co-manager for the offering.
Acasti Pharma Looks Toward Phase III for CaPre with Recent Financing, Analysts Review
Posted on Wednesday October 10, 2018
NEW YORK, NY / ACCESSWIRE / October 10, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...
Acasti Pharma Announces Pricing of $16.6 Million Underwritten Public Offering of Common Shares
Posted on Thursday October 04, 2018
Acasti Pharma Inc. (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, announced today the pricing of an underwritten public offering of 16,600,000 common shares in the United States at a price to the public of $1.00 per share. Acasti Pharma has granted the underwriters a 30-day option to purchase up to 2,490,000 additional common shares sold in the offering, to cover over-allotments, if any. All common shares in the offering are being offered by Acasti Pharma.
The Daily Biotech Pulse: AtriCure's Guidance, Guardant Health And Kodiak To Debut
Posted on Thursday October 04, 2018
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 3) AstraZeneca plc (NYSE: AZN ) Bausch Health Companies ...